^
    Back
    Association details:
    Biomarker:TET2 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:azacitidine (DNMT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

    Excerpt:
    ...- Patients must have a confirmed heterozygous TET2 mutations identified by next generation targeted deep sequencing....
    Trial ID:
    NCT03397173
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES

    Excerpt:
    ...Analyze the incidence of TET2 gene mutations in a series of MDS patients and describe the clinical status of patients carrying mutations Validation of the prognostic potential of TET2 mutations and MPLA screening on: Response rate to treatment with Epo, Lenalidomide and Azacitidine Progression Free Survival (PFS )`Analyze the incidence of TET2 gene mutations and Validation of the prognostic potential of TET2 mutations and MPLA screening...
    Trial ID:
    O-MDS-Protocol
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    1779 Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)

    Published date:
    11/03/2022
    Excerpt:
    The Australasian Leukaemia and Lymphoma Group (ALLG) MDS4 phase II trial randomized 160 patients (pts) with higher risk (by IPSS) myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast acute myeloid leukemia (AML) to either azacitidine (AZA) or combination AZA with lenalidomide....TET2 was the only gene mutation associated with significantly improved benefit when treated with AZA alone (OR 10 [95% CI, 2 to 81]). Median follow up among survivors was 49 months and the median overall survival was 33.2 months (95% CI, 21.7 – NE).
    DOI:
    https://doi.org/10.1182/blood-2022-162880
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Leukemia
    Title:

    Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

    Excerpt:
    We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA...The response rate (including hematological improvement) was 82% in MUT versus 45% in WT patients (P=0.007)...In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA...
    DOI:
    10.1038/leu.2011.71